Online inquiry

IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1596MR)

This product GTTS-WQ1596MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GDF11 gene. The antibody can be applied in Myelodysplastic syndromes (MDS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_005811.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10220
UniProt ID O95390
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1596MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5467MR IVTScrip™ mRNA-Anti-tcdB, CDB-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CDB-1
GTTS-WQ13535MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ15791MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, XmAb-13676(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XmAb-13676
GTTS-WQ11088MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ13472MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ6795MR IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS-8201
GTTS-WQ1311MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ15503MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-7665
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW